Evaluation of the Efficacy of Molnupiravir on Clinical and Laboratory Findings of Patients with moderate COVID-19

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2022年1月11日

试验速览

暂无简介。

•Laboratory confirmation of Coronavirus disease-19 (COVID-19) virus by reverse transcription- polymerase chain reaction (RT-PCR)
•Moderate-severity disease (respiration rate more than 30 per minute, oxygen saturation more than 94%, or pulmonary infiltration less than 50% in both lungs)
•Age over 18 years
•Body mass index less than 40 kilogram per square meters
•No immunosuppressive diseases, including primary and secondary immunodeficiency, consumption of immunosuppressive drugs, organ transplants, chemotherapy or radiotherapy
•Patient willingness to participate in the study
•Existence of oral tolerance
•Non-pregnant and non-lactating women
•Not receiving antiviral drugs and other effective drugs in the treatment of COVID-19 in this clinical course
•No history of severe drug allergy and anaphylactic shock

•Not completing the 5-day treatment period, not completing all visits or laboratory tests
•Development of severe drug hypersensitivity and anaphylactic shock during the study
•Occurrence of oral intolerance in the clinical course

发起方